Pediatric Oncology

ASCO 2022

Questions discussed in this category

In light of the recent rEECur trial interim analysis, would you offer high-dose ifosfamide to an AYA patient with relapsed Ewing's sarcoma who initially had a complete response to up-front therapy?

J Clin Oncol 40, 2022 (suppl 17; abstr LBA2). https://meetings.asco.org/abstracts-presentations/209024

2 Answers available

Papers discussed in this category

Pediatr Blood Cancer, 2022 Oct 02

Irinotecan dose schedule for the treatment of Ewing sarcoma.

Clin Cancer Res, 2023 Jan 09

Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial.

Related Topics in Pediatric Oncology